EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 – AN OVERVIEW
The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a lon...
Saved in:
Published in | Asian journal of pharmaceutical and clinical research pp. 6 - 16 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
07.07.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a longer duration without any life-threatening adverse effects. At present, there are 319 vaccines in various stages of development, of which 16 are authorized for emergency use. Of these 16 vaccines, five vaccines are based on adenoviral vectors. This review is focused on understanding the safety and efficacy of the approved adenoviral vector vaccines for COVID-19, particularly highlighting the interim analysis of phase 3 clinical trials of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine. The efficacy of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine were found to be 70.4%, 95%, 66%, and 65.7%, respectively. Some serious adverse events such as deep vein thrombosis and thrombosis with thrombocytopenia syndrome were observed among AZD1222 and Ad26.COV2.S vaccinated individuals. Meanwhile, Gam-Covid-Vac and AD5- nCOV vaccines did not report any significant adverse events. In addition, we have also focused on the efficacy of these vaccines against SARS-CoV-2 variants such as B.1.1.7, B.1.351, and P.1. Although the efficacy of these approved vaccines against novel SARS-CoV-2 variants, pediatric and geriatric population and long-term efficacy remains uncertain, they are reasonably efficient in preventing mortality due to COVID-19. |
---|---|
AbstractList | The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a longer duration without any life-threatening adverse effects. At present, there are 319 vaccines in various stages of development, of which 16 are authorized for emergency use. Of these 16 vaccines, five vaccines are based on adenoviral vectors. This review is focused on understanding the safety and efficacy of the approved adenoviral vector vaccines for COVID-19, particularly highlighting the interim analysis of phase 3 clinical trials of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine. The efficacy of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine were found to be 70.4%, 95%, 66%, and 65.7%, respectively. Some serious adverse events such as deep vein thrombosis and thrombosis with thrombocytopenia syndrome were observed among AZD1222 and Ad26.COV2.S vaccinated individuals. Meanwhile, Gam-Covid-Vac and AD5- nCOV vaccines did not report any significant adverse events. In addition, we have also focused on the efficacy of these vaccines against SARS-CoV-2 variants such as B.1.1.7, B.1.351, and P.1. Although the efficacy of these approved vaccines against novel SARS-CoV-2 variants, pediatric and geriatric population and long-term efficacy remains uncertain, they are reasonably efficient in preventing mortality due to COVID-19. |
Author | SHANMUGAM, SINDHU VENUGOPAL, PRIYANKA GEORGE, MELVIN SRIRAM, DAMAL KANDADAI |
Author_xml | – sequence: 1 givenname: SINDHU orcidid: 0000-0001-8875-2490 surname: SHANMUGAM fullname: SHANMUGAM, SINDHU – sequence: 2 givenname: PRIYANKA orcidid: 0000-0003-1830-4419 surname: VENUGOPAL fullname: VENUGOPAL, PRIYANKA – sequence: 3 givenname: DAMAL KANDADAI orcidid: 0000-0003-1830-4419 surname: SRIRAM fullname: SRIRAM, DAMAL KANDADAI – sequence: 4 givenname: MELVIN orcidid: 0000-0001-7101-8513 surname: GEORGE fullname: GEORGE, MELVIN |
BookMark | eNpN0OFKwzAQAOAgE5xzz2BeoPWSps3yM3aZFkorXRfxV8nSBDZ0Gy0I_vMdfEOfxFoVPDjuOO7ux3eJJofjwSF0TSCklMTixuxPtgspUBq-knjHQ8ZoQs7QFARnAWWMTP71F2je93sYIhIxJ3yKnpSW-UbWWVngcoXlUhWlziqZY63SuqyCW7lWS6xlmmaFWuNVWeGHSmlV_J2kw_4yIAJ_vn9gOYy0qnSmHq_QuTfPvZv_1hnarFSd3gd5eZelMg8sAUoCtwDfJgIg5m7bCiG2YC1vibdDGmqAOUt4lCSxAGfAJ14I8JQlrF0YS-NohvjPX9sd-75zvjl1uxfTvTUEmhGpGZGab6RmRGpGpOgLs09Xjw |
CitedBy_id | crossref_primary_10_22159_ajpcr_2022_v15i12_46003 |
Cites_doi | 10.1038/nprot.2010.134 10.4110/in.2021.21.e6 10.1136/bmj.m4750 10.1080/21645515.2020.1812313 10.1089/10430340252939023 10.1101/2020.06.12.148726 10.1056/NEJMoa2102214 10.1007/BF02789331 10.1001/jama.2021.7517 10.3390/vaccines2030624 10.1056/NEJMoa2034201 10.1111/cei.13517 10.1016/S0140-6736(21)00432-3 10.1016/j.ejphar.2020.173751 10.3390/v2081681 10.1089/hum.1998.9.17-2577 10.1038/s41591-020-1070-6 10.31219/osf.io/ypgx4 10.1016/j.tibs.2021.03.002 10.1016/S2213-2600(21)00129-6 10.1038/s41586-020-2608-y 10.21203/rs.3.rs-35891/v1 10.15585/mmwr.mm7017e4 10.1385/MB:18:1:63 10.1080/21645515.2020.1735227 10.1016/S0140-6736(20)32661-1 10.1016/S0140-6736(20)31605-6 10.1038/d41586-021-01813-2 10.1038/mtm.2016.30 10.1016/S1473-3099(20)30160-2 10.1038/s41591-021-01408-4 10.1016/j.antiviral.2020.104742 10.1016/S0140-6736(21)00234-8 10.1016/S0140-6736(21)00628-0 10.3389/fmolb.2021.635337 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.22159/ajpcr.2022.v15i7.44261 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 0974-2441 |
EndPage | 16 |
ExternalDocumentID | 10_22159_ajpcr_2022_v15i7_44261 |
GroupedDBID | --- 23N 2WC 53G 5VS AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL CITATION DIK E3Z GX1 HH5 KQ8 M~E OK1 RNS TR2 |
ID | FETCH-LOGICAL-c1021-e80fd690057ebd999b0cc7d1fcd1fa2a04ec17366590ea0f6f990f2464d8ac253 |
ISSN | 0974-2441 |
IngestDate | Fri Aug 23 00:35:21 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1021-e80fd690057ebd999b0cc7d1fcd1fa2a04ec17366590ea0f6f990f2464d8ac253 |
ORCID | 0000-0003-1830-4419 0000-0001-7101-8513 0000-0001-8875-2490 |
PageCount | 11 |
ParticipantIDs | crossref_primary_10_22159_ajpcr_2022_v15i7_44261 |
PublicationCentury | 2000 |
PublicationDate | 2022-07-07 |
PublicationDateYYYYMMDD | 2022-07-07 |
PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-07 day: 07 |
PublicationDecade | 2020 |
PublicationTitle | Asian journal of pharmaceutical and clinical research |
PublicationYear | 2022 |
References | 957924 957968 957925 957969 957926 957927 957928 957929 957971 957972 957973 957930 957974 957931 957975 957932 957976 957933 957977 957934 957978 957970 957935 957979 957936 957937 957938 957939 957982 957983 957940 957984 957941 957985 957942 957986 957943 957987 957944 957988 957945 957989 957980 957981 957946 957947 957948 957949 957993 957950 957994 957951 957995 957952 957953 957954 957955 957956 957990 957991 957992 957957 957958 957959 957960 957961 957962 957963 957920 957964 957921 957965 957922 957966 957923 957967 |
References_xml | – ident: 957978 – ident: 957926 – ident: 957951 – ident: 957940 doi: 10.1038/nprot.2010.134 – ident: 957941 doi: 10.4110/in.2021.21.e6 – ident: 957973 doi: 10.1136/bmj.m4750 – ident: 957925 doi: 10.1080/21645515.2020.1812313 – ident: 957961 – ident: 957938 doi: 10.1089/10430340252939023 – ident: 957949 – ident: 957968 – ident: 957985 doi: 10.1101/2020.06.12.148726 – ident: 957987 doi: 10.1056/NEJMoa2102214 – ident: 957988 – ident: 957935 doi: 10.1007/BF02789331 – ident: 957960 doi: 10.1001/jama.2021.7517 – ident: 957970 – ident: 957931 doi: 10.3390/vaccines2030624 – ident: 957974 – ident: 957993 – ident: 957955 – ident: 957957 doi: 10.1056/NEJMoa2034201 – ident: 957959 – ident: 957954 – ident: 957929 doi: 10.1111/cei.13517 – ident: 957950 – ident: 957923 – ident: 957946 doi: 10.1016/S0140-6736(21)00432-3 – ident: 957928 doi: 10.1016/j.ejphar.2020.173751 – ident: 957981 – ident: 957984 doi: 10.1101/2020.06.12.148726 – ident: 957969 – ident: 957937 doi: 10.3390/v2081681 – ident: 957939 doi: 10.1089/hum.1998.9.17-2577 – ident: 957956 doi: 10.1038/s41591-020-1070-6 – ident: 957989 – ident: 957932 doi: 10.31219/osf.io/ypgx4 – ident: 957942 doi: 10.1016/j.tibs.2021.03.002 – ident: 957980 doi: 10.1016/S2213-2600(21)00129-6 – ident: 957943 doi: 10.1038/s41586-020-2608-y – ident: 957971 – ident: 957933 – ident: 957964 doi: 10.21203/rs.3.rs-35891/v1 – ident: 957979 – ident: 957962 doi: 10.15585/mmwr.mm7017e4 – ident: 957958 – ident: 957975 – ident: 957992 – ident: 957930 – ident: 957936 doi: 10.1385/MB:18:1:63 – ident: 957947 – ident: 957924 – ident: 957963 – ident: 957982 – ident: 957966 – ident: 957920 – ident: 957972 – ident: 957995 – ident: 957921 doi: 10.1080/21645515.2020.1735227 – ident: 957945 doi: 10.1016/S0140-6736(20)32661-1 – ident: 957965 doi: 10.1016/S0140-6736(20)31605-6 – ident: 957953 doi: 10.1038/d41586-021-01813-2 – ident: 957976 – ident: 957991 – ident: 957977 – ident: 957934 doi: 10.1038/mtm.2016.30 – ident: 957944 doi: 10.1016/S1473-3099(20)30160-2 – ident: 957948 doi: 10.1038/s41591-021-01408-4 – ident: 957967 – ident: 957983 – ident: 957990 – ident: 957922 doi: 10.1016/j.antiviral.2020.104742 – ident: 957952 doi: 10.1016/S0140-6736(21)00234-8 – ident: 957986 doi: 10.1016/S0140-6736(21)00628-0 – ident: 957927 doi: 10.3389/fmolb.2021.635337 – ident: 957994 |
SSID | ssj0000395717 |
Score | 2.2923567 |
Snippet | The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines.... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 6 |
Title | EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 – AN OVERVIEW |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjpswFLXS6aabqk_1LS-q2TCkQMAkSzcQkk4CEQkos0JgG7VdpFGbqTRd9R_6H_2ofkmvTXh0FKmdLkDI4Cvje8R9cB8IvWbMtASIVr00haHbJhgoueAETBU-JA7LjULIROFFSKaJ_W7jbHq9n52opct90WffjuaV_A9XYQz4KrNkb8DZhigMwDXwF87AYTj_E4_9lM6Tqm9ONNFgT8MoncV0rqX-eB3F-lu68j0tpeOx7K2hgcEndzz1w3rKGJ73dHOk1TEPA43CjdSPm5iJukKtSrbs1JnYvf_DGa7S4-osy0MFocbTvJrScJEEdKF8rbPQmyb1LVhMEkRLOlfqbDy7oOF5A6pVDG-jJnkgG-baOQ096tHG0Rv4URyocM6FP09nYdeFYVXhrm7XF-naOugZFcjEkbHq60o6YrrK0LwuACzQYGQB1fzjjslqr5bV_2o6H9y-LU3FVubV__mvicImQBFMI0UqU4QySShThDJF6Ba6bbkjR4aQBhuz8ekZ8qenavLcrL4KKVS03hxfVEch6mg263vo7sEkwbTC133UE9sH6HRZ8ffqDK_bFL0vZ_gUL9tq51cP0UULQhxNcAtC3AUhrkGIAYS4BaGcUoMQ__r-A1MYOsDvEUom_no81Q_9OnQmG8TrYmiUnIxkfrMoOFgehcGYy82SwZFbuWELZroDQpyRIXKjJCWoQqVlE5sPc2Y5g8foZPtpK54gbDCz4I7L3BJU5mJU5pxwMF3gg8M5Mbj7FBn1pmW7qixL9heePbv5lOfoTgvXF-hk__lSvAQddF-8Uoz_DdI7cdU |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EVALUATION+OF+ADENOVIRAL+VECTOR-BASED+VACCINES+FOR+PREVENTION+OF+COVID-19+%E2%80%93+AN+OVERVIEW&rft.jtitle=Asian+journal+of+pharmaceutical+and+clinical+research&rft.au=SHANMUGAM%2C+SINDHU&rft.au=VENUGOPAL%2C+PRIYANKA&rft.au=SRIRAM%2C+DAMAL+KANDADAI&rft.au=GEORGE%2C+MELVIN&rft.date=2022-07-07&rft.issn=0974-2441&rft.eissn=0974-2441&rft.spage=6&rft.epage=16&rft_id=info:doi/10.22159%2Fajpcr.2022.v15i7.44261&rft.externalDBID=n%2Fa&rft.externalDocID=10_22159_ajpcr_2022_v15i7_44261 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0974-2441&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0974-2441&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0974-2441&client=summon |